VX-702: Selective ATP-Competitive p38α MAPK Inhibitor for Inflammation Research

Executive Summary: VX-702, a product of APExBIO (SKU A8687), is a potent, highly selective, and ATP-competitive inhibitor of p38α MAP kinase (MAPK14), exhibiting an IC₅₀ of 4–20 nM under standard assay conditions (product page). It demonstrates superior selectivity and affinity over earlier p38 inhibitors, resulting in reproducible suppression of pro-inflammatory cytokines such as IL-6, IL-1β, and TNFα in LPS-primed ex vivo assays (Qiao et al., 2024). VX-702 preserves mitochondrial, metabolic, and functional parameters in stored platelets and restores platelet function after agitation interruption without triggering aggregation or calcium influx. Pharmacokinetic data indicate linear excretion and renal reabsorption with no significant interaction with major renal transporters. VX-702 has demonstrated efficacy in animal models of collagen-induced arthritis and myocardial ischemia-reperfusion injury, making it a leading tool compound for translational inflammation and cardiovascular research.

Biological Rationale

p38α MAP kinase (MAPK14) is a serine/threonine kinase central to cellular responses to pro-inflammatory cytokines, stress, and environmental stimuli (Qiao et al., 2024). It regulates gene expression, cell differentiation, apoptosis, and cytokine biosynthesis. Dysregulation of p38α MAPK signaling is implicated in the pathogenesis of rheumatoid arthritis, acute coronary syndrome, and other inflammatory disorders. Therapeutic targeting of p38α MAPK has been prioritized due to its role at the hub of inflammation signaling pathways. Selective ATP-competitive inhibitors, such as VX-702, enable precise modulation of this pathway, facilitating studies on cytokine suppression, tissue injury, and immune cell function.

Mechanism of Action of VX-702, P38α MAPK inhibitor, highly selective and ATP-competitive

VX-702 binds competitively to the ATP-binding site of human p38α MAP kinase, stabilizing an inactive conformation of the activation loop and rendering the phospho-threonine residue accessible to serine/threonine phosphatases (Qiao et al., 2024). This dual-action mechanism both directly inhibits the kinase catalytic activity and accelerates dephosphorylation by WIP1 phosphatase. VX-702 exhibits an IC₅₀ of 4–20 nM for p38α MAPK in standard kinase assays, with >100-fold selectivity over related kinases (e.g., ERK, JNK). The compound does not induce calcium mobilization or platelet aggregation at effective concentrations. In ex vivo and in vitro models, VX-702 robustly suppresses LPS-induced production of IL-6, IL-1β, and TNFα, which are critical mediators in inflammatory cascades.

Evidence & Benchmarks

• VX-702 inhibits p38α (MAPK14) with an IC₅₀ of 4–20 nM (standard buffer, 25°C, ATP 100 μM) (Qiao et al., 2024).
• Suppresses LPS-induced IL-6, IL-1β, and TNFα production in human whole-blood assays at 10–100 nM, with >90% inhibition at 100 nM (Qiao et al., 2024).
• Maintains mitochondrial integrity and metabolic activity in platelets stored at 22°C for up to 7 days, assessed by flow cytometry and respirometry (BHT920Supplier, 2023).
• Exhibits oral bioavailability and dose-proportional pharmacokinetics in preclinical rat models; linear renal excretion and reabsorption without organic transporter interaction (APExBIO).
• Reduces joint inflammation and erosion in collagen-induced arthritis models, matching the efficacy of methotrexate and prednisolone (5–20 mg/kg oral, 28-day study) (Alpha-1-Antitrypsin, 2023).
• Attenuates myocardial damage and preserves cardiac function post-ischemia/reperfusion by selective p38 MAPK inhibition without affecting ERK or JNK signaling (Qiao et al., 2024).

Applications, Limits & Misconceptions

VX-702 is validated for use in cell-based cytokine assays, ex vivo human blood and platelet studies, and preclinical models of arthritis and cardiac injury. It is not intended for diagnostic or direct clinical use. VX-702's dual-action mechanism—competitive active site binding and promotion of phosphatase-driven dephosphorylation—enables deeper mechanistic studies of MAPK14 regulation compared to traditional inhibitors. For advanced details on cytokine and viability assay optimization, see Optimizing Cytokine and Viability Assays with VX-702 (this article extends prior protocol guidance by mapping mechanistic benchmarks to specific inflammation models).

Common Pitfalls or Misconceptions

• VX-702 is not effective against non-p38 MAPK family kinases such as ERK1/2 or JNK at standard concentrations (≤100 nM).
• It is unsuitable for use in water-based buffers due to insolubility; DMSO or ethanol is required for stock solutions.
• Not intended for human or veterinary therapeutic use; for research only.
• May not replicate efficacy in non-inflammatory or non-MAPK14-dependent models.
• Long-term solution stability is limited; stock solutions should be prepared fresh and stored at -20°C for short-term use.

For a broader discussion of VX-702's dual-action mechanism and translational applications in cardiovascular and arthritis research, consult VX-702 and the Future of p38α MAPK Inhibition: Strategic Insights. This article updates the previous review by providing new evidence on activation loop conformational targeting and phosphatase engagement (Qiao et al., 2024).

For protocol enhancements and workflow optimization, see VX-702: Selective p38α MAPK Inhibitor for Advanced Inflammation Models, which this dossier extends by detailing product-specific storage, solubility, and assay parameterization.

Workflow Integration & Parameters

Preparation: VX-702 is supplied as a solid, insoluble in water but soluble in DMSO (>20.2 mg/mL) or ethanol (>3.88 mg/mL with ultrasonic treatment). Store powder at -20°C. Prepare fresh stock solutions for each experiment and avoid repeated freeze-thaw cycles. Working concentrations in cell-based assays typically range from 10 nM to 1 μM. Use DMSO as the vehicle, ensuring a final concentration ≤0.1% v/v in biological assays to minimize solvent effects. For platelet and blood assays, filter-sterilize solutions and validate activity by cytokine readouts (e.g., ELISA, multiplex flow cytometry). In animal models, follow established oral dosing protocols (e.g., 5–20 mg/kg) and monitor pharmacokinetics and efficacy endpoints.

For full product and workflow details, refer to VX-702, P38α MAPK inhibitor, highly selective and ATP-competitive on the APExBIO website.

Conclusion & Outlook

VX-702 (APExBIO A8687) establishes a new benchmark in selective p38α MAP kinase inhibition for inflammation and cardiovascular research by combining high potency, robust selectivity, and a dual-action mechanism that accelerates activation loop dephosphorylation. Its validated use in ex vivo and in vivo models supports both mechanistic studies and translational research in cytokine signaling, arthritis, and ischemic heart injury. Future directions include integration with advanced screening protocols, investigation in emerging inflammatory models, and application in kinase-phosphatase interaction studies. This article provides a fact-based, evidence-grounded resource for researchers seeking to deploy VX-702 in precision inflammation research.